Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
Researchers Give Update on Janus Kinase (JAK) Inhibitors
Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes
- 1
- 2
- 3
- …
- 5
- Next Page »